We discuss the decision-making frameworks for clinical trials with multiple co-primary endpoints in a group-sequential setting. The decision-making frameworks can account for flexibilities such as a varying number of analyses, equally or unequally spaced increments of information and fixed or adaptive Type I error allocation among endpoints. The frameworks can provide efficiency, i.e., potentially fewer trial participants, than the fixed sample size designs. We investigate the operating characteristics of the decision-making frameworks and provide guidance on constructing efficient group-sequential strategies in clinical trials with multiple co-primary endpoints.
Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.
阅读:5
作者:Hamasaki Toshimitsu, Asakura Koko, Evans Scott R, Sugimoto Tomoyuki, Sozu Takashi
| 期刊: | Statistics in Biopharmaceutical Research | 影响因子: | 1.300 |
| 时间: | 2015 | 起止号: | 2015;7(1):36-54 |
| doi: | 10.1080/19466315.2014.1003090 | ||
特别声明
1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。
4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。
